CN107923917A - 瓜氨酸化在诊断疾病中的作用 - Google Patents

瓜氨酸化在诊断疾病中的作用 Download PDF

Info

Publication number
CN107923917A
CN107923917A CN201680044624.0A CN201680044624A CN107923917A CN 107923917 A CN107923917 A CN 107923917A CN 201680044624 A CN201680044624 A CN 201680044624A CN 107923917 A CN107923917 A CN 107923917A
Authority
CN
China
Prior art keywords
seq
citrullinated
leu
arg
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680044624.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·凡艾克
J·福特博伯
E·科荣格
R·侯维斯凯
本杰明·菲利普·伯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of CN107923917A publication Critical patent/CN107923917A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680044624.0A 2015-06-18 2016-06-20 瓜氨酸化在诊断疾病中的作用 Pending CN107923917A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562181665P 2015-06-18 2015-06-18
US62/181,665 2015-06-18
US201562233231P 2015-09-25 2015-09-25
US62/233,231 2015-09-25
US201562387149P 2015-12-23 2015-12-23
US62/387,149 2015-12-23
PCT/US2016/038439 WO2016205828A2 (en) 2015-06-18 2016-06-20 Role of citrullination in diagnosing diseases

Publications (1)

Publication Number Publication Date
CN107923917A true CN107923917A (zh) 2018-04-17

Family

ID=57546510

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680044624.0A Pending CN107923917A (zh) 2015-06-18 2016-06-20 瓜氨酸化在诊断疾病中的作用

Country Status (5)

Country Link
US (1) US11105817B2 (cg-RX-API-DMAC7.html)
EP (1) EP3311176A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018524575A (cg-RX-API-DMAC7.html)
CN (1) CN107923917A (cg-RX-API-DMAC7.html)
WO (1) WO2016205828A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases
CN118001407A (zh) * 2024-04-02 2024-05-10 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11988676B2 (en) 2017-11-16 2024-05-21 Brainbox Solutions, Inc. Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
EP4032969A4 (en) * 2019-09-17 2023-08-16 Kikkoman Corporation METHOD FOR QUANTIFICATION OF CITRULLINE, OXIDOREDUCTASE FOR QUANTIFICATION, COMPOSITION FOR QUANTIFICATION, QUANTIFICATION KIT AND METHOD FOR EVALUATION OF PEPTIDYLARGININE DEIMINASE ACTIVITY
CN114839364B (zh) * 2022-04-27 2025-09-12 珠海丽珠试剂股份有限公司 抗突变型瓜氨酸化波形蛋白抗体检测试剂盒及其应用
EP4609859A1 (en) * 2024-02-28 2025-09-03 Universidad Pablo de Olavide Inhibitors of the gene smpd1 for the treatment of spinal muscular atrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155226A (ja) * 2007-12-25 2009-07-16 Tokyo Metropolitan Foundation For Social Welfare & Public Health 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途
US20140308676A1 (en) * 2010-11-12 2014-10-16 Justyna P. Fert-Bober Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537757B2 (en) 1999-12-23 2009-05-26 Childrens Hospital Los Angeles Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
ES2314621T3 (es) 2004-02-27 2009-03-16 F. Hoffmann-La Roche Ag Procedimiento de evaluacion de la artritis reumotoidea, mediante la medicion de anti-ccp y amiloide a serico.
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
GB0803107D0 (en) 2008-02-20 2008-03-26 Axis Shield Diagnostics Ltd Method
US9063148B2 (en) 2008-10-22 2015-06-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicince, Inc. Immunoassays for citrullinated proteins
JP5866206B2 (ja) 2009-03-10 2016-02-17 デューク ユニバーシティ 冠動脈疾患および心血管イベントのリスクの予測
CA2757444A1 (en) 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
GB201213012D0 (en) 2012-07-23 2012-09-05 Univ Warwick Diagnostic for determining skelektal health
WO2014037911A1 (en) 2012-09-10 2014-03-13 Koninklijke Philips N.V. System and method for estimating susceptibility to a medical condition
JP6365863B2 (ja) * 2013-07-16 2018-08-01 国立大学法人 熊本大学 質量分析におけるペプチドピークの同定・定量のためのデータベース作成方法
EP3311176A4 (en) 2015-06-18 2019-03-13 Cedars-Sinai Medical Center ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155226A (ja) * 2007-12-25 2009-07-16 Tokyo Metropolitan Foundation For Social Welfare & Public Health 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途
US20140308676A1 (en) * 2010-11-12 2014-10-16 Justyna P. Fert-Bober Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases
CN118001407A (zh) * 2024-04-02 2024-05-10 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Also Published As

Publication number Publication date
WO2016205828A2 (en) 2016-12-22
US20180299467A1 (en) 2018-10-18
EP3311176A4 (en) 2019-03-13
US11105817B2 (en) 2021-08-31
WO2016205828A3 (en) 2017-02-02
JP2018524575A (ja) 2018-08-30
EP3311176A2 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
US11105817B2 (en) Role of citrullination in diagnosing diseases
CN102395886B (zh) 用于对修饰的肽进行定量的方法
JP6826543B2 (ja) アルツハイマー病に関係する生体分子
WO2017053739A1 (en) Methods and compositions for tauopathy diagnosis and treatment
Audano et al. Zc3h10 is a novel mitochondrial regulator
JP5701994B2 (ja) シトルリン化タンパク質：生理学的および病理学的疾患のマーカーとしての心筋タンパク質の翻訳後修飾
Kusić et al. Striated muscle-specific serine/threonine-protein kinase beta segregates with high versus low responsiveness to endurance exercise training
Pineda et al. Proteomics studies of the interactome of RNA polymerase II C-terminal repeated domain
Birner et al. Proteomic profiling implies mitochondrial dysfunction in tachycardia-induced heart failure
Gebriel et al. Zebrafish brain proteomics reveals central proteins involved in neurodegeneration
Schulenborg et al. Proteomics in neurodegeneration–disease driven approaches
CN108473529A (zh) 检测和治疗肺高压的方法
Baumgärtel et al. Changes in the proteome after neuronal zif268 overexpression
Choi et al. Proteomic analysis of the skeletal muscles from dysferlinopathy patients
Muller et al. Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples
Sato et al. Proteomic analysis of masticatory muscle tendon–aponeurosis hyperplasia: A preliminary study using a 2D-DIGE system
Azotla-Vilchis et al. Identification of dystrophin Dp71dΔ71-associated proteins in PC12 cells by quantitative proteomics
US20140004530A1 (en) Method for the evaluation of compound-target interactions across species
Ubaida-Mohien et al. Analysis of the skeletal muscle proteome uncovers alteration in splicing, mitochondria, and immune factors with aging
US20230144446A1 (en) Blood-based diagnostic assays for alzheimer's disease
HK40110041A (en) Blood-based diagnostic assays for alzheimer's disease
Arachchige Development of tools for phosphosite-specific kinase identification and discovery of phosphatase substrates
Abbasi Molecular Mechanisms Influencing Functional Status in Fragile-X Syndrome Investigated by Mass Spectrometry-based Proteomics
US20070269830A1 (en) Process for the Identification of New Medical Targets
Heaven Proteomic Analysis of Rosenthal Fibers and the Development of Software for Proteomics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417